Topical Calcineurin Inhibitors, Keratinocyte Carcinoma, and Risk in Atopic Dermatitis
Investigators sought to assess the overall keratinocyte carcinoma risk and by subtype in adults with atopic dermatitis exposed to topical calcineurin inhibitors.
Dermatitis
Gestational Weight Gain Tied to Childhood Allergic Conditions
Excessive gestational weight gain (GWG) may be a risk factor for childhood allergic diseases.
Triamcinolone Injection May Be Effective Treatment Option for Melasma
The efficacy and safety of intralesional triamcinolone vs Kligman’s formula in treatment of melasma was assessed.
Dupilumab Use for Atopic Dermatitis Remains High at 1 Year
A study sought to characterize adults with atopic dermatitis who initiated dupilumab and evaluate persistence on therapy.
Dupilumab vs Cyclosporin for Treatment of Atopic Dermatitis
Drug survival of dupilumab compared with cyclosporin, the reasons for drug discontinuation, and the predictive parameters of drug survival were analyzed.
Abrocitinib May be a Promising Atopic Dermatitis Treatment in Adolescents, Adults
The efficacy and safety of abrocitinib monotherapy in adolescents and adults with moderate to severe atopic dermatitis is assessed.
Delgocitinib Cream Gets Fast Track Status for Chronic Hand Eczema
Delgocitinib is a topical pan-Janus kinase (JAK) inhibitor that blocks the activation of the JAK-STAT pathway.
Atopic Dermatitis Incidence May Be Lower in Infants With Early-Life Farm Exposure
Pre- and early postnatal farm exposure was found to be associated with reduced incidence of atopic dermatitis in infants.
Dry Eye Disease, Food Allergies Linked to Dupilumab-Induced Ocular AEs in Patients With AD
Therapy-induced ocular adverse events may be associated with pre-existing dry eye disease, eyelid eczema, and a history of a food allergy, among other conditions.
Dupilumab for AD May Reduce Work, School Absenteeism
Dupilumab displayed significant reductions in work and school absenteeism with associated cost savings.
-
Loading...
-
Loading...
Next post in Dermatitis
